Physician profile
Igor Chernyavskiy
NPI 1477520245
$6,738.67
in general payments reported to CMS, 2019-2025
25 companies · $943 in 2025
The $943 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,917 · 2020: $925 · 2021: $1,101 · 2022: $554 · 2023: $538 · 2024: $760 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223 · Education: $17.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.35 |
| Education | $17.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,548.88 | 2019-2025 | Trelegy Ellipta, Nucala |
| Veran Medical Technologies, INC. | $873.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $779.40 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $688.85 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $606.69 | 2019-2025 | Ofev |
| Philips North America LLC | $428.23 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $367.75 | 2020-2021 | |
| Harmony Biosciences LLC | $360.93 | 2021-2025 | |
| Galvanize Therapeutics, INC | $144.11 | 2024 | Aliya System |
| Olympus America INC. | $125.00 | 2022 | |
| Genentech USA, INC. | $124.77 | 2019 | |
| Mylan Specialty L.P. | $122.98 | 2021-2023 | Yupelri |
| Mallinckrodt Enterprises LLC | $118.39 | 2019 | |
| Fisher & Paykel Healthcare INC | $74.50 | 2024 | Fisher & Paykel Healthcare |
| Insmed, INC. | $67.63 | 2020-2024 | Arikayce |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $54.21 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $44.95 | 2019 | |
| 3b Medical, INC. | $42.01 | 2024 | Luna |
| Ventec Life Systems, INC. | $41.67 | 2020 | |
| Jazz Pharmaceuticals INC. | $41.04 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.96 | 2021 | |
| Circassia INC. | $20.15 | 2021 | |
| Baxter Healthcare | $17.47 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $12.70 | 2019 | |
| Inogen, INC. | $9.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Chernyavskiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.